Conclusion
Know-how and Knowledge Management in pharmaceutical R&D
Quizzed article REF: PHA3070 V1
Conclusion
Know-how and Knowledge Management in pharmaceutical R&D

Authors : Sacha ROUAH, Mélisande BERNARD

Publication date: June 10, 2020, Review date: May 10, 2021 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

5. Conclusion

Privacy policies can be a double-edged sword. They are of the utmost importance in companies with only summary procedures, or where such measures are totally absent. However, in companies that already have restrictive confidentiality circles in place, the introduction of additional measures can have a detrimental effect, in particular by giving rise to the withholding of information on the part of employees. Indeed, by informing players that the data they hold has a significant economic value, they may be tempted to keep it before it reaches internal distribution systems. This policy of omerta must not be allowed to hinder research projects, whether within a laboratory or in the context of collaborative projects. While there are many ways in which research can be hampered by a lack of exploitation of know-how, excessive protection can also limit the latter.

However,...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Article included in this offer

"Drugs and pharmaceuticals"

( 125 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us